INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Derivative conversionVerified data

Koe Gary S. reported ETRA

Chief Technical Officer · Electra Therapeutics, Inc. · Common Stock

Side
C
Value
—
Shares
63.7K
Price
—
Executed
Sep 21, 2026
Disclosed
Sep 21, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Sep 21 executedSep 21, 2026 disclosed

ETRA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Derivative conversion — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ETRA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    PG
    Parry GrahamChief Scientific Officer
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    85.5K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    KS
    Koe Gary S.Chief Technical Officer
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    63.7K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DK
    Dong Quehuong (Kathy)Director, President & CEO
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    455.5K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SN
    Stagliano NancyDirector
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    255.6K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    PG
    Parry GrahamChief Scientific Officer
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    85.5K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DK
    Dong Quehuong (Kathy)Director, President & CEO
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    455.5K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SN
    Stagliano NancyDirector
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    255.6K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002153365-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 21, 2026
    Published
    Sep 21, 2026
    Ingested by INSIDER
    Nov 5, 02:16 UTC
    Last re-read
    Nov 5, 02:16 UTC

    Extracted facts

    Filer
    Koe Gary S.
    Role
    Chief Technical Officer
    Transaction
    Derivative conversionAs filed: “C”
    Asset
    Electra Therapeutics, Inc.
    Ticker
    ETRA
    Shares
    63.7K
    Execution date (reported)
    Sep 21, 2026
    Owned after transaction
    63.7K shares
    Days from execution to publication
    0

    What this establishes

    Koe Gary S. filed this Form 4 reporting a derivative conversion of ETRA on Sep 21, 2026. It became public on Sep 21, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Technical Officer
    Koe Gary S.cik:0002153365
    Issuer
    Electra Therapeutics, Inc.cik:0002088082

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.